Polling Questions


< All Questions
According to the webcast:

With Stanley E. Althof, PhD
Results of the co-primary endpoint of improvement in desire change in female sexual function index desire domain (FSFI-D) score from baseline to end of core (double-blind) phase of the RECONNECT study confirmed that:
 a. Compared with placebo women taking bremelanotide (BMT) did not have any significantly increased scores on the desire domain of the FSFI at 6 months
 b. A vast majority of participants did not respond well to this phase of the study
 c. Compared with placebo women taking BMT had significantly increased scores on the desire domain of the FSFI at 6 months
 d. The FSFI-D scores were not significantly different
 
 

Your answers are confidential and will be used for educational purposes only.

Submit